Introduction
Angiotensin II (Ang II) is very important in the regulation of cardiovascular function. Physiologically it maintains salt and water homeostasis and blood pressure (BP) regulation. Despite extensive studies, it is difficult to precisely define the effect of Ang II because of multiple interactions between sodium intake (or body sodium), Ang II and aldosterone. These three variables all affect BP, cardiac and vascular growth as well as each other. Ang II can cause cardiac and vascular hypertrophy, but this is prevented or reduced by a low-salt intake which by itself elevates Ang II levels. 1, 2 Likewise, a high-salt intake causes cardiac hypertrophy despite Ang II levels. 3 Aldosterone can cause hypertension, cardiac hypertrophy and cardiac fibrosis, 4 but it is not clear whether this can occur in the absence of sodium retention. It is therefore difficult to dissect which of the above factors are important. It is probably the balance between all three.
The effect of Ang II can be blocked in two major ways. First by preventing or reducing its formation and second by blocking its action on the AT 1 -receptor. 5, 6 While the action of AT 1 -receptor antagonists (ARB) is highly specific, effects other than those mediated by the AT 1 -receptor may develop because of the presence of AT 2 -receptors. 6 While angiotensinconverting enzyme (ACE) inhibition may selectively block ACE, the outcome is relatively non-selective as this enzyme catalyses the breakdown of other vasoactive substances (e.g., bradykinin). Thus, while we regard the two groups of compounds as working by preventing Ang II effects, multiple other effects may result, highlighting the differences between the two classes of drugs.
Ang II is formed in circulating plasma and in tissue. In plasma, renin released by the kidney cleaves angiotensin I (Ang I) from angiotensinogen produced by the liver and Ang I is converted to Ang II by ACE. This active peptide then binds to an AT 1 -or AT 2 -receptor, to exert its effect. This classic pathway also exists in the tissues but, in addition, other enzymes can form Ang II. 7 ACE is membrane-bound with its catalytic site outside the cell. It may be located close to the receptor and thus local formation and action is important.
Ang II exerts a powerful feedback control on renin secretion (the so-called short loop). 8 As Ang II levels fall, more renin is secreted and thus there is more catalytic breakdown of angiotensinogen. This powerful physiological response may thus negate in part the blockage of Ang II formation or its action. If an ACE inhibitor (ACE-I) is given,Ang I will accumulate to a level that may overcome the pharmacological inhibition. If the effect of Ang II on the AT 1 -receptor is blocked,Ang II accumulates to a level that may overcome the blockade. When an ACE-I is given to rats or people, plasma Ang II levels fall initially but with chronic administration Ang II returns to levels close to the value before therapy, though the hypotensive response persists. 9, 10 This probably highlights the importance of the tissue formation of Ang II.
A mouse model in which the attachment of ACE to the membrane was prevented, supports the important role of Ang II formation in tissue. 11 While there were changes in circulating renin and angiotensin levels, these were not profoundly different from normal. However, the mice were extremely hypotensive and had polyuria. This infers that the local formation of Ang II is of critical importance to maintain cardiovascular normality. Ang II also affects the other components of the renin-angiotensinogen reaction and increases the synthesis of angiotensinogen. 12 There is therefore a positive feedback mechanism which in usual circumstances is balanced by the negative feedback on renin synthesis and secretion.
Thus, while ARBs and ACE-I both prevent Ang II effects, the overall outcome may differ. This means that the response to one class cannot be assumed to represent the response to the other class. In addition, it means that combining ARBs and ACE-I may have beneficial effects compared with increasing the dose of either compound alone.
Experimental studies Hypertension
When an ARB is added to an ACE-I, there is a further fall in BP. 13, 14 However, increasing the dose of the ACE-I will also increase the response. In a study conducted in spontaneously hypertensive rats (SHR) with BP measured by telemetry, we have recently investigated whether a similar maximal fall can be achieved with monotherapy of losartan or lisinopril as with the combination. 15 Rats were given sequentially increasing doses of lisinopril until a plateau was achieved. They were then given the dose immediately before the plateau together with losartan 10 mg/kg. Subsequently, losartan was titrated until a plateau was achieved and they were then given the dose of losartan immediately before the plateau together with lisinopril, 10 mg/kg. 15 There seems to be an additive effect from the combination which cannot be achieved by increasing the dose of either individual agent (Table 1 ). In addition, at the time of peak response to an acute dose, the ACE inhibition appeared more effective than the ARB.
Cardiac hypertrophy
Cardiac hypertrophy is frequently associated with hypertension and increases morbidity and mortality. It appears to result from an interaction between wall stress, cardiac work and the local and circulating humoral environment. 16 A number of studies [17] [18] [19] have investigated this problem and attempted to determine the relative importance of BP levels compared with 'complete' blockade of Ang II action. Kim et al. 17 conducted a study in which they compared the effect of the addition of either the calcium channel blocker amlodipine or the ARB candesartan to rats receiving the ACE-I perindopril. With a dose of each of these three drugs (perindopril, 2 mg/kg/d; candesartan 2 mg/kg/d; amlodipine 3 mg/kg/d) that lowered BP to a similar extent the ACE-I and the ARB reduced cardiac size to a greater extent than amlodipine. When one tenth of the dose of perindopril and candesartan (which had no effect on BP as monotherapy), were given together BP fell to a similar extent as with the higher doses, and cardiac hypertrophy resolved.
Adding a dose of amlodipine (0.5 mg/kg/d) to perindopril or candesartan (0.2 mg/kg/d) caused a small fall in BP and a small resolution in cardiac hypertrophy. This was not as great as with can-desartan+perindopril (0.2 mg/kg/d). Finally a dose of perindopril (0.05 mg/kg/d) and candesartan (0.05 mg/kg/d) caused a similar BP fall to the combination therapy containing amlodipine, but a greater resolution of cardiac hypertrophy. Thus, combining subtherapeutic doses of ARB and ACE-I allowed a fall in BP and resolution of left ventricular hypertrophy (LVH) greater than was achieved with therapeutic doses of amlodipine (Figure 1 ). For the same level of BP the therapy with amlodipine was always associated with a higher relative cardiac weight (left ventricular weight/BW) than therapy to block the Ang II effect, either as high-dose monotherapy or low-dose combination therapy.
In SHR on the usual French rat diet (NaCl=0.4%) large doses of combined enalapril and losartan caused hypotension, marked cardiac involution, and death of the rats with prolonged treatment. 18 In both SHR and Sprague-Dawley rats this syndrome could be prevented by a high-salt intake (4%) ( Table 2) and reversed by providing 0.45% NaCl as the drinking water. 19 The syndrome developed at the same time as angiotensinogen levels became depleted (and thus Ang II would cease to have an effect). The high-salt intake reduced the rise in renin and prevented the angiotensinogen depletion. As the drug doses used in the study were extremely high, it is highly improbable that this situation would ever occur in humans.
Renal disease
In experimental renal disease in the 5/6 renal mass ablation rat Ots et al. 20 found no difference between combined therapy with enalapril+losartan and monotherapy provided there was comparable reduction in BP. In this model with blockade of Ang II action the focal glomerulosclerosis score correlated (r=0.68) with BP level in individual rats, emphasising that both BP and Ang II blockade are important to determine the outcome.
Experimental summary
From different experimental models it appears that combining AIIAs and ACE-I has a greater effect than using higher doses of the drug as monotherapy.This is possibly due to more complete blockade of the tissue renin-angiotensin system (RAS).
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Figure 1
Relationship between blood pressure and relative left ventricular (LV) weight.The graph indicates a close link between blood pressure and relative LV weight on treatment with either high-dose monotherapy or lowdose combinations of ACE inhibitor and ARB ( ), but this is different to the relationship when blood pressure is reduced to a similar extent by the calcium channel blocker amlodipine ( ). LVW = left ventricular weight, BW = body weight. Amlodipine as monotherapy or in combination with perindopril or candesartan; candesartan or perindopril as monotherapy; candesartan and perindopril in combination, (a) 1/10 of monotherapy dose, (b) very low dose, 1/400 of usual dose; r untreated. Drawn from data in paper by Kim et al. 17 
Clinical studies Hypertension
Initial studies suggested that provided sufficient doses were used, the response to ACE-I and ARBs would be similar. BP fell in parallel groups to a similar extent with both agents. [21] [22] [23] However, in a recent study, the antihypertensive response at the end of the dosing interval was greater with candesartan than with enalapril, reflecting the long duration of action of candesartan. 23 Some studies 24 have demonstrated that when losartan is added to lisinopril there is a greater effect than doubling the dose of lisinopril. In addition, plasma renin and Ang I rose to a greater extent, confirming that despite the ACE inhibition there was still physiological feedback on renin secretion possibly due to tissue conversion. A recent study by Sever 25 implies that people who respond to monotherapy on ARBs may not respond to monotherapy with ACE-I and vice versa. This may reflect the ability of some people to convert Ang I to Ang II in the tissues by alternative pathways, or alternatively different concentrations and/or location of the AT 1receptor or even different amounts of AT 2 -receptors. If different people respond to the two drugs it is not surprising that combination therapy has a greater overall effect.
Heart failure
Paradoxically the role of combination therapy has been more extensively investigated in heart failure than in hypertension. At present there are no completed or conclusive studies which show that either ARBs or their combination with ACE-I improve the prognosis. However, various parameters improve in people with heart failure in the experimental and clinical setting. In a relatively small study 26 it has been demonstrated that adding irbesartan to conventional therapy that included ACE inhibition, was well tolerated and produced favourable trends (i.e., exercise tolerance time and left ventricular ejection fraction improved). The RESOLVD Pilot Study 27 compared candesartan (4, 8 or 16 mg) with candesartan (4 or 8 mg)+enalapril, 20 mg and with enalapril, 20 mg in 768 patients with heart failure over a 43-week period.There were no differences between groups with regard to effects on exercise tolerance, NYHA functional class or quality of life. BP decreased more with combination therapy than with monotherapy. With combination therapy there was only a minor increase in end-diastolic and end-systolic volumes, which was significantly less than observed with the monotherapies, and ejection fraction increased more in the combination groups. Thus, combination therapy appeared to be more beneficial in its effects on left ventricular modelling. Furthermore, brain natriuretic peptide decreased more with the combination therapy. Whether the improvements observed with the combination are due to the lower BP or to a more complete blockade of Ang II effects is not clear.
Renal disease Diabetic
A number of smaller studies had indicated that ARBs or their combination with ACE-I may be useful in diabetic patients with proteinuria. In a recent study 28 in such patients candesartan,16 mg was as effective as lisinopril, 20 mg at reducing both BP and urinary albumin/creatinine ratio over a 12-week period. In the second part of the study combining the two therapies for another 12 weeks caused a further reduction in systolic and diastolic BP (10/6 mmHg) compared with monotherapy. There was also a trend towards a further reduction in microalbuminuria with the combination. The combination was well tolerated and is clearly an effective antihypertensive agent in diabetic patients. Although it was not determined if similar effects might have been achieved by increasing the doses of monotherapy, the doses used in the study are close to the plateau of the antihypertensive dose-responsive curve.
Non diabetic
Several studies [29] [30] [31] have examined the effect of combination therapy in patients with renal disease. Overall the combination has been well tolerated. 29 Using an ACE-I and an ARB caused a greater reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy than doubling the dose of either the ACE-I or the ARB. 30 The antiproteinuria effect of either drug type alone or REVIEW Table 2 Interaction between sodium intake and blockade of the renin angiotensin system with an ACE inhibitor and an AT 1 -receptor antagonist. 19 Reduced sodium intake 0.2% High sodium intake 4% the combination did not appear to depend on the reduction in BP or changes in creatinine clearance. Kincaid-Smith 31 has recently reported the effect of adding candesartan, 8 mg to patients (n=53) with proteinuria and BP controlled with an ACE-I. Serum creatinine was slightly elevated (0.18 mmol/l). There was a small change in BP (from 133/82 to 127/79, p<0.001) with candesartan and urine protein fell by about (25% [2.4 to 1.8 g/ 24-hour], p<0.001). There was no change in serum creatinine or potassium levels. Thus in patients with proteinurea and renal disease the addition of candesartan had clinical benefits (Table 3) , although long-term studies of the effect on morbidity and mortality are needed.
Conclusion
The combination of an ARB with an ACE-I appears to have additional effects over and above those obtained by increasing the dose of either component as monotherapy. The combination is well tolerated but results in rats stress the importance of the sodium intake of the rat in determining the outcome. This combination may have specific benefits in resistant hypertension, in cardiac failure and in renal disease. Studies are needed to define the exact place and whether there is a superior improvement in morbidity and mortality. 
